Botulinum Toxin Resistance and Antibody Formation: Clinical Implications
This guide covers the clinical science of botulinum toxin resistance: what causes it, how to distinguish true immunological non-response from pseudo-resistance, which products carry the lowest immunogenicity risk, and how to manage patients who have developed or are developing resistance. It is one of the most clinically important topics in long-term toxin practice, and one that becomes increasingly relevant as patient treatment histories lengthen.
Botulax vs Nabota vs Bocouture vs Dysport: Which Toxin Should Your Clinic Stock?
The botulinum toxin market has expanded significantly over the past decade. Where UK and European practitioners once had a limited choice of two or three products, today's market offers a growing range of formulations from manufacturers in South Korea, Germany, France, and the United States — each with different protein loads, unit strengths, onset profiles, and price points.
